Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Gilead Sciences 7.803, Incyte 1.674.
Gilead Sciences vs Incyte: Revenue Comparison
Gilead Sciences (GILD) and Incyte (INCY) are peers in Healthcare. Gilead Sciences reported revenue of $7.8B as of Q2 2026, compared with $1.7B for Incyte. Gilead Sciences leads on revenue.
Gilead Sciences's gross margin is 79.8% versus 93.7% for Incyte. Gilead Sciences's net margin is -134.5% versus 35.0% for Incyte.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Gilead Sciences, Incyte.| Metric | Gilead Sciences | Incyte |
|---|---|---|
| Market Cap | - | - |
| Revenue | $7.80B | $1.67B |
| Cost of Revenue | $1.58B | $105.00M |
| Gross Profit | $6.22B | $1.57B |
| Operating Income | $-10.39B | $698.00M |
| Net Income | $-10.50B | $586.00M |
| R&D Expense | $1.76B | $517.00M |
| Earnings Per Share | -$8.45 | $2.81 |
| Gross Margin | 79.8% | 93.7% |
| Operating Margin | -133.2% | 41.7% |
| Net Profit Margin | -134.5% | 35.0% |
| Free Cash Flow | $3.69B | $495.00M |
| Cumulative Free Cash Flow | $155.83B | $3.86B |
| Operating Cash Flow | $3.57B | $508.00M |
| Cash & Equivalents | $3.18B | $3.98B |